Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nabilone has been approved to treat chemotherapy-induced nausea and vomiting. Recent studies have explored cannabinoids in pain management. OBJECTIVES: To review the evidence for the use of cannabinoids in general and nabilone in particular; i) in managing chemotherapy-induced nausea and vomiting; and ii) in treating pain. METHOD: A systematic review of published English literature used the terms: cancer, cannabinoid, nabilone, nausea, pain, tetrahydrocannabinol and vomiting as search terms. Reviews, meta-analyses and treatment trials were reviewed. RESULTS/CONCLUSIONS: Nabilone is superior to placebo, domperidone and prochlorperazine but not metoclopramide or chlorpromazine. Cannabinoids do not add to benefits of 5-HT(3) receptor antagonists. Side effects are greater for nabilone than for prochlorperazine, in most studies patients prefered nabilone over prochlorperazine. Nabilone is ineffective in acute pain but benefits in neuropathic pain and central hypersensitization. Recent guidelines place nabilone as a second to fourth line drug for neuropathic pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 2×
“Cannabinoids uniquely inhibit neurotransmitter release or DSI but do not prevent spontaneous firing of neurons (implying benefits in neuropathic central hypersensitivity and chronic pain, which is stimulus evoked, such as occurs with allodynia, rather than spontaneous or acute pain) [14,34] .”
BackgroundKatona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 1×
“CB1 receptors can be found on presynaptic neuron membranes of GABAergic interneurons [10,21,22] .”
BackgroundNeuroanatomy of the pain system and of the pathways that modulate pain
Willis, W. D., & Westlund, K. N. (1997) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-199701000-00002 · Cited by 924 · cited 1×
“Cannabinoids also activate nociceptive inhibitory α 2 adrenoceptors, which descend from the brain stem to the spinal cord [15,16] .”
BackgroundFunctional characteristics of the midbrain periaqueductal gray.
Behbehani, M. M. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00009-k · Cited by 879
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827 · cited 2×
“4 Other cannabinoids in pain management Multiple studies have used ∆ 9 -THC in the management of spastic neuropathic pain in multiple sclerosis [112-117] .”
BackgroundKatona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668 · cited 1×
“CB1 receptors can be found on presynaptic neuron membranes of GABAergic interneurons [10,21,22] .”
BackgroundCannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.16 · Cited by 610
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608 · cited 2×
“CB1 receptors are sparse in the brain stem, which accounts for the relatively low risk for respiratory depression with cannabinoids alone [8-10] .”
BackgroundCannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253187.66183.9c · Cited by 598 · cited 1×
“Smoked cannabis reduces HIV-related neuropathic pain by a third compared with placebo [120] .”
BackgroundWade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589 · cited 2×
“Also, combinations of ∆ 9 -THC and cannabidiol as a sublingual spray have been used for the same purpose [115,118] .”
BackgroundMethodSvendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500 · cited 1×
“4 Other cannabinoids in pain management Multiple studies have used ∆ 9 -THC in the management of spastic neuropathic pain in multiple sclerosis [112-117] .”
Activation of Corticotropin-Releasing Factor in the Limbic System During Cannabinoid Withdrawal
Rodrı́guez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., & Weiss, F. (1997) · Science · doi:10.1126/science.276.5321.2050 · Cited by 499 · cited 2×
“Dexamethasone reduces expression of CB1 receptors by 30%, dopamine receptor antagonists (D2 antagonists) increase CB1 expression by 45% and N -methylD -aspartate receptor antagonists reduce expression by 30 – 50% [44-47] .”
BackgroundAgurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06861-9 · Cited by 406 · cited 1×
“The two former cannabinoids do have anticonvulsant activity [48] .”
BackgroundAntiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy
Sallan, S. E., Zinberg, N. E., & Frei, E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510162931603 · Cited by 364 · cited 1×
“Dronabinol and nabilone when used for chemotherapy-induced nausea and vomiting have response rates and side effects which appear to be very similar in type and prevalence [84-89] .”
BackgroundNotcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03674.x · Cited by 305 · cited 1×
“4 Other cannabinoids in pain management Multiple studies have used ∆ 9 -THC in the management of spastic neuropathic pain in multiple sclerosis [112-117] .”
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x158066 · Cited by 216 · cited 1×
“The greatest evidence is for ∆ 9 -THC or the combination of ∆ 9 -THC and cannabidiol [121] .”
BackgroundMeiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H.-M., & Baranowski, V. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x167525 · Cited by 214
Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0218-8 · Cited by 171
Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration
Cichewicz, D. L., & McCarthy, E. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045575 · Cited by 154 · cited 2×
“Increased antinociception in animals occurs with the combination of cannabinoids and opioids [64]”
BackgroundThe Enhancement of Morphine Antinociception in Mice by Î9-Tetrahydrocannabinol
Smith, F. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00012-4 · Cited by 146
Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0611-4 · Cited by 96
The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord injury
Hagenbach, U., Luz, S., Ghafoor, N., Berger, J. M., Grotenhermen, F., Brenneisen, R., & Mäder, M. (2007) · Spinal Cord · doi:10.1038/sj.sc.3101982 · Cited by 70
Passik, S. D., Kirsh, K. L., Theobald, D. E., Dickerson, P., Trowbridge, R., Gray, D., Beaver, M., Comparet, J., & Brown, J. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00078-2 · Cited by 56 · cited 1×
“Recent research in antiemetics has not further explored cannabinoids [100-104] .”
Background
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Aviram, J. (2017) · Pain Physician · doi:10.36076/ppj.20.5.e755 · Cited by 305
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Smith, L. A., Azariah, F., Lavender, V. T., Stoner, N. S., & Bettiol, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009464.pub2 · Cited by 255
Navari, R. M. (2013) · Drugs · doi:10.1007/s40265-013-0019-1 · Cited by 174
“A few reported studies have explored this mechanism in patients [72, 73].”
Background
Metadata
- Authors
- Davis, M. P.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2007-12-20
- Volume
- 17
- Issue
- 1
- Pages
- 85-95
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2169082912
- Cited by
- 82
- References
- 24
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.